stockgist
HomeTop MoversCompaniesConcepts

Market

  • Top Movers
  • Companies
  • Concepts

SEC Filings

  • AI Filing Analysis
  • Financial Reports
  • Current Reports
  • IPO Filings

Ownership

  • Institutional Holdings
  • Insider Trading

About

  • Data updates every 5 min
  • SEC EDGAR Source
© 2025–2026 StockGist|Information only, not investment advice
    1. Companies
    2. LXRX
    stockgist
    HomeTop MoversCompaniesConcepts
    LXRX logo

    Lexicon Pharmaceuticals, Inc.

    LXRX
    NASDAQ
    Healthcare
    Biotechnology
    The Woodlands, TX, US103 employeeslexpharma.com
    $1.59
    -0.04(-2.74%)

    Mkt Cap $676M

    $0.49
    $1.76

    52-Week Range

    At a Glance

    AI-generated

    Lexicon Pharmaceuticals reported total revenues of $49.8 million for FY 2025, a 60% increase from $31.1 million in FY 2024.

    Revenue breakdown: License (89.9%), Product (10.1%).

    $676M

    Market Cap

    $58M

    Revenue

    -$59M

    Net Income

    Employees103
    Fundamentals

    How The Business Makes Money

    Revenue by Segment

    License89.9%($210M)
    Product10.1%($24M)
    Activity

    What Changed Recently

    Financial Results
    Mar 4, 2026

    Results of Operation and Financial Condition On March 5, 2026, we issu ed a press release to report our financial results for the quarter and year ended Decembe

    Material Agreement+5 More
    Feb 1, 2026

    Entry into a Material Definitive Agreement Underwriting Agreement On January 29, 2026, Lexicon Pharmaceuticals, Inc. (the “ Company ”) entered into an Underwrit

    Financial Results+3 More
    Jan 28, 2026

    Results of Operations and Financial Disclosure The Company previously announced that it ended 2025 with cash, investments and restricted cash of $125.2 million

    Peer Companies

    CompanyPriceChangeMarket CapP/E
    RAPTRAPT Therapeutics, Inc.$58.01+0.00%$959M-14.8
    OMEROmeros Corporation$10.94-9.44%$776M-5.8
    CMPXCompass Therapeutics, Inc...$5.46+0.55%$755M-14.0
    OCGNOcugen, Inc.$1.78-0.28%$585M-9.7
    FDMT4D Molecular Therapeutics...$9.49-3.85%$484M-3.8
    ADCTADC Therapeutics S.A.$3.80+0.03%$483M-4.3
    FULCFulcrum Therapeutics, Inc...$8.06+7.75%$436M-5.8
    BCYCBicycle Therapeutics plc$5.06+3.27%$350M-1.4
    Analyst View
    Company Profile
    CIK0001062822
    ISINUS5288723027
    CUSIP528872302
    Phone281 863 3000
    Address2445 Technology Forest Boulevard, The Woodlands, TX, 77381, US
    SEC EDGAR

    Market

    • Top Movers
    • Companies
    • Concepts

    SEC Filings

    • AI Filing Analysis
    • Financial Reports
    • Current Reports
    • IPO Filings

    Ownership

    • Institutional Holdings
    • Insider Trading

    About

    • Data updates every 5 min
    • SEC EDGAR Source
    © 2025–2026 StockGist|Information only, not investment advice